Insights

Why BioCryst Stock Shot Nearly 5% Higher Today

What happened
American biotech BioCryst Pharmaceuticals (NASDAQ: BCRX) scored an important regulatory win across the Atlantic Ocean on Wednesday. As a result, happy shareholders pushed the company’s stock almost 5% higher on the day.
So what
BioCryst announced that the European Medicines Agency (EMA) — a regulator for the sprawling, multi-country European Union — has granted the company’s BCX9250 investigational drug access to the EMA’s Priority Medicines (PRIME) initiative. This is a treatment targeting fibrodysplasia ossificans progressiva (FOP), an affliction in which patients suffer the ossification of ligaments and tendons. 

Image source: Getty Images.

The EMA describes PRIME as an effort “to enhance support for the development of medicines that target an unmet medical need.” It is similar to efforts in other jurisdictions aimed at encouraging the development and commercialization of such treatments. FOP certainly fits the bill, as it is a very rare disease throughout the world.
BioCryst didn’t hesitate to point out that BCX9250 is the first investigational drug for its indication to enter the PRIME program. 
The biotech quoted its chief research and development officer Helen Thackray as saying that “Promising results from non-clinical data and the first-in-human Phase 1 safety, tolerability and pharmacokinetics study in healthy subjects formed the basis of the application for PRIME eligibility.”
“We look forward to applying the benefits available to us through PRIME as we continue to advance our ALK-2 inhibitor program,” she added.
Now what
BCX9250 certainly has potential, but investors should keep in mind that it is early days for the pipeline drug. According to BioCryst, in a phase 1 clinical trial it was demonstrated to be safe and well-tolerated by the participants. Significantly more research is forthcoming.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. –

What happened

American biotech BioCryst Pharmaceuticals (NASDAQ: BCRX) scored an important regulatory win across the Atlantic Ocean on Wednesday. As a result, happy shareholders pushed the company’s stock almost 5% higher on the day.

So what

BioCryst announced that the European Medicines Agency (EMA) — a regulator for the sprawling, multi-country European Union — has granted the company’s BCX9250 investigational drug access to the EMA’s Priority Medicines (PRIME) initiative. This is a treatment targeting fibrodysplasia ossificans progressiva (FOP), an affliction in which patients suffer the ossification of ligaments and tendons. 

Image source: Getty Images.

The EMA describes PRIME as an effort “to enhance support for the development of medicines that target an unmet medical need.” It is similar to efforts in other jurisdictions aimed at encouraging the development and commercialization of such treatments. FOP certainly fits the bill, as it is a very rare disease throughout the world.

BioCryst didn’t hesitate to point out that BCX9250 is the first investigational drug for its indication to enter the PRIME program. 

The biotech quoted its chief research and development officer Helen Thackray as saying that “Promising results from non-clinical data and the first-in-human Phase 1 safety, tolerability and pharmacokinetics study in healthy subjects formed the basis of the application for PRIME eligibility.”

“We look forward to applying the benefits available to us through PRIME as we continue to advance our ALK-2 inhibitor program,” she added.

Now what

BCX9250 certainly has potential, but investors should keep in mind that it is early days for the pipeline drug. According to BioCryst, in a phase 1 clinical trial it was demonstrated to be safe and well-tolerated by the participants. Significantly more research is forthcoming.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!